Related Experiment Videos
Invited review: the evolution of antidepressant mechanisms
D A Slattery1, A L Hudson, D J Nutt
1Psychopharmacology Unit, School of Medical Sciences, University Walk, University of Bristol, Bristol BS8 1TD, UK.
Fundamental & Clinical Pharmacology
|January 30, 2004
Summary
Current antidepressants, descendants of 1950s discoveries like monoamine oxidase inhibitors, remain effective. Research explores novel targets and downstream effects for faster-acting depression treatments, but traditional options lead the market.
Area of Science:
- Neuroscience
- Pharmacology
- Psychiatry
Background:
- Antidepressant development originated from serendipitous 1950s findings of iproniazid and imipramine.
- The 1960s mechanistic studies of these drugs and others led to the monoamine theories of depression.
Observation:
- Monoamine theories, focusing on noradrenaline and 5-hydroxytryptamine, dominated research for 40 years.
- Recent research investigates downstream alterations and novel targets identified through animal models for new antidepressants.
- Clinical trials are underway for some novel targets.
Findings:
- Monoamine antidepressants, despite decades of research, remain the most effective current treatments.
- New drug development aims for faster onset and broader efficacy.
- Novel targets are being explored, but market leadership remains with established monoamine-based therapies.
Implications:
- Established monoamine antidepressants are likely to remain market leaders for the foreseeable future.
- Continued research into novel targets may yield future therapeutic advancements.
- Understanding downstream effects could refine existing treatments or inform new drug design.